Quince Therapeutics, INC Form 4 insider transactions

Quince Therapeutics director David Lamond was granted 2,700 stock options as part of a standard equity compensation package.

Director Christopher J. Senner was granted 2,700 stock options in Quince Therapeutics, Inc. as part of a standard equity compensation arrangement.

Chief Corporate Affairs Officer Brigette Roberts reports the exchange of Orphai Therapeutics stock options for Quince Therapeutics options following a merger.

Quince Therapeutics' CEO and CMO, Dirk Thye, was granted 1,000,000 employee stock options with an exercise price of $3.08, vesting monthly through December 2029.

Quince Therapeutics President Charles S. Ryan acquired 200,000 employee stock options with an exercise price of $3.08, vesting through December 2029.

Brendan Hannah, Quince Therapeutics' CBO, COO, and CCO, was granted 365,000 employee stock options with an exercise price of $3.08.

Christopher J. Senner, a director at Quince Therapeutics, Inc., acquired 21,810 stock options in lieu of his 2026 cash retainer.

Quince Therapeutics Director Margaret McLoughlin elected to receive 19,547 stock options in lieu of her 2026 annual cash retainer.

Quince Therapeutics director David Lamond elected to receive 29,423 stock options in lieu of his 2026 annual cash retainer, aligning his interests with shareholders.

Quince Therapeutics Director June Bray elected to receive 18,724 stock options in lieu of her 2026 annual cash retainer.

A director at Quince Therapeutics, Luca Benatti, sold 50,000 shares of common stock for a weighted average price of $3.47 per share.

Quince Therapeutics Director Luca Benatti acquired 8,918 shares of common stock on October 23, 2024, as part of a pre-arranged release related to the EryDel Italy Inc. acquisition.

Quince Therapeutics CEO and CMO Dirk Thye transferred 739,885 common shares from direct ownership to an indirect ownership via the Thye Trust.

Brendan Hannah, CBO, COO & CCO of Quince Therapeutics, Inc., increased his direct beneficial ownership by exercising employee stock options.

Brendan Hannah, Chief Business Officer, Chief Operating Officer, and Chief Commercial Officer of Quince Therapeutics, Inc. (QNCX), acquired 37,736 common shares and 37,736 warrants on June 18, 2025.

Charles S. Ryan, President of Quince Therapeutics, Inc., acquired 7,548 common shares and 7,548 warrants on June 18, 2025, as part of a Rule 10b5-1 trading plan.

Quince Therapeutics' CEO and CMO, Dirk Thye, has significantly increased his direct beneficial ownership in the company by acquiring 150,944 common shares and an equal number of warrants.

Una S. Ryan, a Director at Quince Therapeutics, Inc., has elected to receive 27,000 stock options in lieu of her 2025 annual cash retainer, aligning her compensation with shareholder interests.

Quince Therapeutics, Inc. Director Luca Benatti was granted 27,000 stock options with an exercise price of $1.09, vesting in one year, as part of his 2025 annual director compensation.

Christopher J. Senner, a Director at Quince Therapeutics, Inc. (QNCX), has acquired 27,000 stock options with an exercise price of $1.09, vesting on June 4, 2026, in lieu of his 2025 annual cash retainer.

Quince Therapeutics Director David Lamond was granted 27,000 stock options with an exercise price of $1.09, vesting in one year, as part of his 2025 director compensation.

Quince Therapeutics, Inc. director Margaret McLoughlin was granted 27,000 stock options with an exercise price of $1.09, vesting in one year, as part of her 2025 annual director compensation.

Rajiv Patni, a Director at Quince Therapeutics, Inc. (QNCX), has opted to receive 27,000 stock options in lieu of his annual cash retainer for 2025, aligning his compensation with shareholder interests.

Quince Therapeutics Director June Bray has been granted 27,000 stock options with an exercise price of $1.09, vesting in one year, as part of her 2025 annual director compensation.

Dirk Thye, CEO and Chief Medical Officer of Quince Therapeutics, reports the acquisition of stock options.

Charles S. Ryan, President of Quince Therapeutics, acquired 300,000 employee stock options on January 28, 2025, according to a Form 4 filing.

Brendan Hannah, CBO, COO, and CCO of Quince Therapeutics, Inc., reports the acquisition of stock options.

Margaret McLoughlin, a director at Quince Therapeutics, received stock options in lieu of her 2025 annual cash retainer.

Director June Bray acquired 30,282 stock options in Quince Therapeutics in lieu of a cash retainer.

Director David Lamond acquired 47,587 stock options in Quince Therapeutics in lieu of his 2025 annual cash retainer.